Presentation (CTI)

OBJECTIVES: This study aimed to estimate healthcare resource utilization (HCRU) and direct costs of Chronic Myeloid Leukemia (CML) in the Brazilian public healthcare system (SUS).
METHODS: Observational study using data from the Ambulatory Information System (SIA) and Hospital Information System (SIH). It included patients aged 18 or older with at least one claim of the International Classification of Diseases (ICD-10) code C92.1, from January 2013 to December 2023. Patients were classified as ‘chronic’ based on chemotherapy procedures. Lines of therapy (LOT) were defined as the number of Tyrosine kinase inhibitors prescriptions.
RESULTS: The study involved 13,162 patients, predominantly male (55.0%), white (46.0%), with an average age of 51 years (IQR: 39-63) and follow-up time of 4.0 years, mainly from Southeast Brazil (44.0%). Among them, 11,946 (90.8%) were in the chronic phase. On average, CML patients had 42.8 (SD: 33.2) chemotherapy visits. Hospitalization occurred in 2,202 patients (16.7%) with an average stay of 10.4 days, and 229 (10.4%) required Intensive Care Unit (ICU). In the chronic cohort, patients averaged 31.9 (SD: 30.6) chemotherapy visits in LOT1 and 16.6 (SD: 18.6) in LOT3. The highest hospitalization rates were in LOT3 (12.6%) and LOT4 (12.4%), with the longest stay in LOT4 (14.3 days). ICU use was higher in LOT3 (18.5%) and LOT5+ (16.7%). Total treatment costs for CML patients in SUS were USD 26,41M for outpatient visits and USD 8,92M for hospitalizations. Outpatient visit average costs per patient ranged from USD 907.85 in LOT1 to USD 2,780.61 in LOT3, while hospitalization costs ranged from USD 2,046.80 in LOT1 to USD 10,709.18 in LOT4 in the chronic phase.
CONCLUSIONS: The study provides an overview of HCRU and direct costs in treating CML within the SUS. Advanced LOTs are associated with significantly higher costs and resource demands, particularly due to increased hospitalizations and ICU admissions.